Study of the effects of blocking the enzyme PCSK9 on artery wall inflamation

Registry ID

EUCTR2015-003731-35

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Amgen Inc

Start date

2015-11-06

Completion date

2018-04-05

Last update

2026-08-16

Conditions

• Hypercholesterolemia

Summary

To evaluate the effect of evolocumab on arterial wall inflammation, as measured by percent change from baseline in target-to-background ratio of an index vessel by FDG-PET/CT at week 16 in subjects with baseline lipoprotein (a) [Lp(a)] ≥ 50 mg/dL and low density lipoprotein-cholesterol (LDL-C) ≥ 100 mg/dL

Locations

• , , Netherlands

Related clinical trials

• A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
• Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
• Causes and Natural History of Dyslipidemias
• A Post-Marketing Clinical Trial of Pemafibrate in Patients ｗith Hypercholesterolemia and Inadequate Response to Statins
• A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors
• Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD

View on source registry